Transfusion strategies in patients with cirrhosis

Patricia Liu, Justine Hum, Janice Jou, Richard M. Scanlan, Joseph Shatzel

Research output: Contribution to journalReview article

Abstract

Bleeding related to portal hypertension and coagulopathy is a common complication in patients with cirrhosis. Complications and management of bleeding is a significant source of healthcare cost and utilization, as well as morbidity and mortality. Due to the scarcity of evidence surrounding transfusion strategies and hemostatic interventions in patients with cirrhosis, there has been significant debate regarding the best practice. Emerging data suggest that evidence supporting transfusion of packed red blood cells to a hemoglobin threshold of 7-8 g/dL is strong. thrombopoietin (TPO) receptor agonists have shown promise in increasing platelet levels and reducing transfusions preprocedurally, although have not specifically been found to reduce bleeding risk. Data for viscoelastic testing (VET)-guided transfusions appear favorable for reducing blood transfusion requirements prior to minor procedures and during orthotopic liver transplantation. Hemostatic agents such as recombinant factor VIIa, prothrombin complex concentrates, and tranexamic acid have been examined but their role in cirrhotic patients is unclear. Other areas of growing interest include balanced ratio and whole blood transfusion. In the following manuscript, we summarize the most up to date evidence for threshold-guided, VET-guided, balanced-ratio, and whole blood transfusions as well as the use of hemostatic agents in cirrhotic patients to provide practice guidance to clinicians.

Original languageEnglish (US)
Pages (from-to)15-25
Number of pages11
JournalEuropean Journal of Haematology
Volume104
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

Fibrosis
Hemostatics
Blood Transfusion
Hemorrhage
Thrombopoietin Receptors
Tranexamic Acid
Erythrocyte Transfusion
Manuscripts
Portal Hypertension
Practice Guidelines
Health Care Costs
Liver Transplantation
Hemoglobins
Blood Platelets
Morbidity
Mortality

Keywords

  • blood coagulation disorders
  • blood component transfusion
  • gastrointestinal hemorrhage
  • liver cirrhosis
  • viscoelastic testing

ASJC Scopus subject areas

  • Hematology

Cite this

Transfusion strategies in patients with cirrhosis. / Liu, Patricia; Hum, Justine; Jou, Janice; Scanlan, Richard M.; Shatzel, Joseph.

In: European Journal of Haematology, Vol. 104, No. 1, 01.01.2020, p. 15-25.

Research output: Contribution to journalReview article

Liu, Patricia ; Hum, Justine ; Jou, Janice ; Scanlan, Richard M. ; Shatzel, Joseph. / Transfusion strategies in patients with cirrhosis. In: European Journal of Haematology. 2020 ; Vol. 104, No. 1. pp. 15-25.
@article{e33cad528b4e49f7841db59e5f1b86d7,
title = "Transfusion strategies in patients with cirrhosis",
abstract = "Bleeding related to portal hypertension and coagulopathy is a common complication in patients with cirrhosis. Complications and management of bleeding is a significant source of healthcare cost and utilization, as well as morbidity and mortality. Due to the scarcity of evidence surrounding transfusion strategies and hemostatic interventions in patients with cirrhosis, there has been significant debate regarding the best practice. Emerging data suggest that evidence supporting transfusion of packed red blood cells to a hemoglobin threshold of 7-8 g/dL is strong. thrombopoietin (TPO) receptor agonists have shown promise in increasing platelet levels and reducing transfusions preprocedurally, although have not specifically been found to reduce bleeding risk. Data for viscoelastic testing (VET)-guided transfusions appear favorable for reducing blood transfusion requirements prior to minor procedures and during orthotopic liver transplantation. Hemostatic agents such as recombinant factor VIIa, prothrombin complex concentrates, and tranexamic acid have been examined but their role in cirrhotic patients is unclear. Other areas of growing interest include balanced ratio and whole blood transfusion. In the following manuscript, we summarize the most up to date evidence for threshold-guided, VET-guided, balanced-ratio, and whole blood transfusions as well as the use of hemostatic agents in cirrhotic patients to provide practice guidance to clinicians.",
keywords = "blood coagulation disorders, blood component transfusion, gastrointestinal hemorrhage, liver cirrhosis, viscoelastic testing",
author = "Patricia Liu and Justine Hum and Janice Jou and Scanlan, {Richard M.} and Joseph Shatzel",
year = "2020",
month = "1",
day = "1",
doi = "10.1111/ejh.13342",
language = "English (US)",
volume = "104",
pages = "15--25",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Transfusion strategies in patients with cirrhosis

AU - Liu, Patricia

AU - Hum, Justine

AU - Jou, Janice

AU - Scanlan, Richard M.

AU - Shatzel, Joseph

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Bleeding related to portal hypertension and coagulopathy is a common complication in patients with cirrhosis. Complications and management of bleeding is a significant source of healthcare cost and utilization, as well as morbidity and mortality. Due to the scarcity of evidence surrounding transfusion strategies and hemostatic interventions in patients with cirrhosis, there has been significant debate regarding the best practice. Emerging data suggest that evidence supporting transfusion of packed red blood cells to a hemoglobin threshold of 7-8 g/dL is strong. thrombopoietin (TPO) receptor agonists have shown promise in increasing platelet levels and reducing transfusions preprocedurally, although have not specifically been found to reduce bleeding risk. Data for viscoelastic testing (VET)-guided transfusions appear favorable for reducing blood transfusion requirements prior to minor procedures and during orthotopic liver transplantation. Hemostatic agents such as recombinant factor VIIa, prothrombin complex concentrates, and tranexamic acid have been examined but their role in cirrhotic patients is unclear. Other areas of growing interest include balanced ratio and whole blood transfusion. In the following manuscript, we summarize the most up to date evidence for threshold-guided, VET-guided, balanced-ratio, and whole blood transfusions as well as the use of hemostatic agents in cirrhotic patients to provide practice guidance to clinicians.

AB - Bleeding related to portal hypertension and coagulopathy is a common complication in patients with cirrhosis. Complications and management of bleeding is a significant source of healthcare cost and utilization, as well as morbidity and mortality. Due to the scarcity of evidence surrounding transfusion strategies and hemostatic interventions in patients with cirrhosis, there has been significant debate regarding the best practice. Emerging data suggest that evidence supporting transfusion of packed red blood cells to a hemoglobin threshold of 7-8 g/dL is strong. thrombopoietin (TPO) receptor agonists have shown promise in increasing platelet levels and reducing transfusions preprocedurally, although have not specifically been found to reduce bleeding risk. Data for viscoelastic testing (VET)-guided transfusions appear favorable for reducing blood transfusion requirements prior to minor procedures and during orthotopic liver transplantation. Hemostatic agents such as recombinant factor VIIa, prothrombin complex concentrates, and tranexamic acid have been examined but their role in cirrhotic patients is unclear. Other areas of growing interest include balanced ratio and whole blood transfusion. In the following manuscript, we summarize the most up to date evidence for threshold-guided, VET-guided, balanced-ratio, and whole blood transfusions as well as the use of hemostatic agents in cirrhotic patients to provide practice guidance to clinicians.

KW - blood coagulation disorders

KW - blood component transfusion

KW - gastrointestinal hemorrhage

KW - liver cirrhosis

KW - viscoelastic testing

UR - http://www.scopus.com/inward/record.url?scp=85075195376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075195376&partnerID=8YFLogxK

U2 - 10.1111/ejh.13342

DO - 10.1111/ejh.13342

M3 - Review article

C2 - 31661175

AN - SCOPUS:85075195376

VL - 104

SP - 15

EP - 25

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -